Mansoor Muhammad Khalid, Hussain Iftikhar, Arshad Muhammad, Muhammad Ghulam
Department of Microbiology, Faculty of Veterinary Science, University of Agriculture, Faisalabad 38040, Pakistan.
Trop Anim Health Prod. 2011 Feb;43(2):331-8. doi: 10.1007/s11250-010-9694-z. Epub 2010 Sep 28.
The current study was planned to develop an efficient vaccine against hydropericardium syndrome virus (HSV). Currently, formalin-inactivated liver organ vaccines failed to protect the Pakistan broiler industry from this destructive disease of economic importance. A field isolate of the pathogenic hydropericardium syndrome virus was adapted to chicken embryos after four blind passages. The chicken embryo-adapted virus was further serially passaged (12 times) to get complete attenuation. Groups of broiler chickens free from maternal antibodies against HSV at the age of 14 days were immunized either with 16th passage attenuated HSV vaccine or commercially formalized liver organ vaccine. The antibody response, measured by enzyme-linked immunosorbent assay was significantly higher (P < 0.05) in the group immunized with the 16th passage attenuated HSV vaccine compared to the group immunized with liver organ vaccine at 7, 14, and 21 days post-immunization. At 24 days of age, the broiler chickens in each group were challenged with 10(3.83) embryo infectious dose(50) of pathogenic HSV and were observed for 7 days post-challenge. Vaccination with the 16th passage attenuated HSV gave 94.73% protection as validated on the basis of clinical signs (5.26%), gross lesions in the liver and heart (5.26%), histopathological lesions in the liver (1.5 ± 0.20), and mortality (5.26%). The birds inoculated with liver organ vaccine showed significantly low (p < 0.05; 55%) protection estimated on the basis of clinical signs (40%), gross lesions in the liver and heart (45%), histopathological lesions in the liver (2.7 ± 0.72), and mortality (35%). Birds in the unvaccinated control group showed high morbidity (84%), mortality (70%), gross (85%), and histopathological lesions (3.79 ± 0.14) with only 10% protection. In conclusion, this newly developed HSV vaccine proved to be immunogenic and has potential for controlling HSV infections in chickens.
本研究旨在研发一种高效的抗心包积水综合征病毒(HSV)疫苗。目前,福尔马林灭活肝脏器官疫苗未能保护巴基斯坦肉鸡产业免受这种具有经济重要性的毁灭性疾病的侵害。一株致病性心包积水综合征病毒的野外分离株经4次盲传后适应鸡胚。鸡胚适应病毒进一步连续传代(12次)以实现完全减毒。14日龄无母源抗HSV抗体的肉鸡群,分别用第16代减毒HSV疫苗或市售福尔马林处理的肝脏器官疫苗进行免疫。通过酶联免疫吸附测定法测得的抗体反应,在免疫后7、14和21天,与接种肝脏器官疫苗的组相比,接种第16代减毒HSV疫苗的组显著更高(P<0.05)。在24日龄时,每组肉鸡用10(3.83) 鸡胚感染剂量(50) 的致病性HSV进行攻毒,并在攻毒后观察7天。根据临床症状(5.26%)、肝脏和心脏的大体病变(5.26%)、肝脏的组织病理学病变(1.5±0.20)以及死亡率(5.26%)验证,接种第16代减毒HSV疫苗提供了94.73%的保护。接种肝脏器官疫苗的鸡,根据临床症状(40%)、肝脏和心脏的大体病变(45%)、肝脏的组织病理学病变(2.7±0.72)以及死亡率(35%)估计,显示出显著较低(p<0.05;55%)的保护。未接种疫苗的对照组鸡发病率高(84%)、死亡率高(70%)、大体病变(85%)和组织病理学病变(3.79±0.14),仅10%得到保护。总之,这种新研发的HSV疫苗被证明具有免疫原性,对控制鸡的HSV感染具有潜力。